肺免疫预后指数在局部晚期非小细胞肺癌中的预后价值验证研究
该研究回顾性分析了2000至2017年接受放疗的1079例局部晚期非小细胞肺癌(LA-NSCLC)患者,验证基线肺免疫预后指数(LIPI)的预后价值。结果显示,LIPI中-差组(1或2分)患者的总生存(OS)、无进展生存(PFS)、局部区域无复发生存(LRRFS)和远处无转移生存(DMFS)均劣于LIPI良好组(0分)。多因素分析提示LIPI是不可手术LA-NSCLC患者OS、PFS和LRRFS的独立预后因素,倾向性评分匹配分析进一步验证了该结果。
要点
- 基线LIPI中-差组LA-NSCLC患者接受放疗后OS、PFS、LRRFS和DMFS均较差。
- 多因素分析显示LIPI是OS(HR=1.19)、PFS(HR=1.18)和LRRFS(HR=1.22)的独立预后因素。
- 倾向性评分匹配分析进一步验证LIPI中-差组与更短生存独立相关。
核心结论
- LIPI是用于不可切除局部晚期非小细胞肺癌患者的一种简单且有前景的预后标志物。
研究设计与样本
- 回顾性研究,纳入2000至2017年接受放疗的1079例局部晚期非小细胞肺癌患者。
主要发现
- LIPI中-差组(1或2分)患者OS、PFS、LRRFS和DMFS均劣于LIPI良好组(0分)。
- 多因素分析显示LIPI是OS(HR=1.19,95%CI:1.02-1.40)、PFS(HR=1.18,95%CI:1.02-1.36)和LRRFS(HR=1.22,95%CI:1.05-1.41)的独立预后因素。
- 倾向性评分匹配分析进一步验证LIPI中-差组是OS、PFS和LRRFS更短的独立预后因素。
关键数值与推荐
- LIPI基于治疗前dNLR和LDH水平构建,0分为良好组,1或2分为中-差组。
临床怎么用
- 治疗前计算LIPI有助于对不可切除LA-NSCLC放疗患者进行预后分层。
- LIPI中-差组患者预后较差,或需更密切随访及强化治疗策略。
局限性
- 本研究为回顾性研究,尚需前瞻性研究验证上述发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Baseline lung immune prognostic index (LIPI) was reported as a potential predictive biomarker of immune checkpoint inhibitor treatment and a prognostic biomarker for metastatic non-small cell lung cancer (NSCLC). However, it remains unclear whether LIPI is associated with outcomes in locally advanced NSCLC (LA-NSCLC). MATERIALS/METHODS: Patients with LA-NSCLC receiving radiotherapy between 2000 to 2017 were retrospectively reviewed. Based on pretreatment dNLR and LDH level made up LIPI per previous publications, patients were divided into good group (0 score) and intermediate-poor group (1 or 2 scores). Propensity score matching (PSM) was conducted to balance confounding variables. RESULTS: A total of 1079 patients were eligible for analysis. Patients with intermediate-poor pretreatment LIPI had inferior overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS) than those with good LIPI. Multivariate analysis suggested that LIPI was an independent prognostic marker for OS (hazard ratio [HR] = 1.19, 95% CI: 1.02-1.40), PFS (HR = 1.18, 95% CI: 1.02-1.36), and LRRFS (HR = 1.22, 95% CI: 1.05-1.41) in patients with inoperable LA-NSCLC. PSM analysis further verified that intermediate-poor LIPI was an independent prognostic factor for shorter survivals (OS, PFS and LRRFS). CONCLUSIONS: LIPI is a simple and promising prognostic marker for patients with unresectable LA-NSCLC. Further prospected studies are warranted to validated these findings.
引用
- Zhang T, Xue W, Wang D, et al. A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer. Radiother Oncol. 2021. PMID: 33418003. doi:10.1016/j.radonc.2020.12.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。